Rectiv (Nitroglycerin) Patent Expiration, LOE Window & CMS Spending

Rectiv (Nitroglycerin) by Aptalis/Allerga: Off-Patent Genericized (AB Competition), 5 AB generics, $3.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAptalis/Allerga
FDA Application & PathwayN021359 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel